Relationship between the effect of cyclophosphamide on adjuvant arthritis severity, skin allograft rejection and spleen cell cytotoxic activity in rats

Clicks: 368
ID: 265903
1990
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Cyclophosphamide, which has a poor immunosuppressive effect on adjuvant arthritis in rats, evokes an aggravating form of the disease when applied at a single low dose before rats' sensitization with complete Freund's adjuvant. However, cyclophosphamide administered by this method of treatment has no …
Reference Key
l1990methodsrelationship Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Marinova-Mutafchieva L;Altankov G;Neronov A;Goranov I;;
Journal Methods and findings in experimental and clinical pharmacology
Year 1990
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/2319832
Keywords
immunity National Center for Biotechnology Information NCBI NLM MEDLINE animals pubmed abstract nih national institutes of health national library of medicine Rats spleen / drug effects arthritis experimental / drug therapy* inbred strains pmid:2319832 l marinova-mutafchieva g altankov i goranov arthritis / drug therapy* cell survival / drug effects* chromium radioisotopes cyclophosphamide / pharmacology* graft rejection / drug effects* cellular / drug effects skin transplantation spleen / cytology spleen / immunology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.